CliffBio
small molecule

KHEDEZLA

DESVENLAFAXINE

Loss of exclusivity—loss of exclusivity
CompanyOsmotica Pharmaceutical →See this company's full patent-cliff portfolio

Drug detail

Brand nameKHEDEZLA
Active ingredientDESVENLAFAXINE
Strength50MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2013
Marketing statusDISCN

More from Osmotica Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

KHEDEZLA patent cliff — loss of exclusivity — | CliffBio